MyChesCo on MSN5h
Johnson & Johnson Highlights Promising Data on Investigational Autoantibody Drug Nipocalimab
Johnson & Johnson has unveiled groundbreaking findings on nipocalimab, an investigational FcRn blocker, in a recent ...
Healio18h
NIH trial to test safety, efficacy of monoclonal antibody for dengue
The NIH announced that it is launching a phase 2 human challenge trial of AV-1, an investigational monoclonal antibody to ...
Zacks.com on MSN23h
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
Ultragenyx Pharmaceutical RARE reported fourth-quarter 2024 loss of $1.39 per share, wider than the Zacks Consensus Estimate ...
Cure Today1d
Linvoseltamab BLA Resubmission Accepted by FDA for Review
The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...